Brainstorm Cell Therapeutics Inc. BCLI
0.81 USD -0.02 (-1.85%)
Nov 4, 2026, 12:38 PM EST
0.8108 Day range 0.8261
0.46 52-week range 1.69
- YTD
- +47.42%
- 1 year
- +19.24%
News
prnewswire.com BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions Executive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models.
prnewswire.com BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial…
benzinga.com Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027 New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker…
prnewswire.com BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic…
prnewswire.com BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June…
prnewswire.com BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell…
prnewswire.com BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market $2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of…
prnewswire.com BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial…
defenseworld.net Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF) Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast…
defenseworld.net Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving…
prnewswire.com BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort…
defenseworld.net Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Passes Above 200-Day Moving Average – Should You Sell? Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.65 and…
defenseworld.net Brainstorm Cell Therapeutics (BCLI) Expected to Announce Quarterly Earnings on Monday Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Brainstorm Cell Therapeutics…
prnewswire.com Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has…
prnewswire.com Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has…
prnewswire.com BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update NEW YORK , Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial…
businesswire.com Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Brainstorm Cell Therapeutics Inc. (OTCMKTS: BCLI) breached their…
seekingalpha.com Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript Brainstorm Cell Therapeutics Inc. (OTC:BCLI) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Alla Patlis - Interim CFO & Controller Chaim Lebovits - President & CEO…
prnewswire.com BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK , Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading…
prnewswire.com BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK , Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
prnewswire.com BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB NEW YORK , July 17, 2025 BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification from The Nasdaq Stock Market LLC, informing the company that…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Earnings Scheduled For May 15, 2025
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Earnings Scheduled For March 31, 2025
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per…
- benzinga.com Earnings Scheduled For November 14, 2023 Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
- benzinga.com Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday saw 132 companies set new 52-week lows.
- benzinga.com Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
- benzinga.com Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.
- benzinga.com Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.